{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:13:30Z","timestamp":1791821610829,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alzheimer\u2019s Association Research Fellowship","award":["AARF-23-1141384"],"award-info":[{"award-number":["AARF-23-1141384"]}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP23\/00039"],"award-info":[{"award-number":["CP23\/00039"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00155"],"award-info":[{"award-number":["PI19\/00155"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["LX22NPO5107"],"award-info":[{"award-number":["LX22NPO5107"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche Diagnostics International Ltd."},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["948677"],"award-info":[{"award-number":["948677"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ERA PerMed","award":["ERAPERMED2021-184"],"award-info":[{"award-number":["ERAPERMED2021-184"]}]},{"name":"LaCaixa Foundation","award":["100010434"],"award-info":[{"award-number":["100010434"]}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["LCF\/BQ\/PR21\/11840004"],"award-info":[{"award-number":["LCF\/BQ\/PR21\/11840004"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) exhibits sex differences in prevalence, symptoms and risk factors. Understanding the effect of sex in AD cerebrospinal fluid (CSF) biomarkers and their association with amyloid-beta (A\u03b2) pathology in preclinical stages have important implications for their use in prevention trials. The objective of this study was to examine sex differences in core AD CSF biomarkers used in early diagnosis and prevention trials, as well as in CSF biomarkers reflecting downstream pathophysiological mechanisms, and in their associations with A\u03b2 pathology\u00a0as measured by\u00a0Positron Emission Tomography (PET).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cognitively Unimpaired (CU) participants from the ALFA\u2009+\u2009(N\u2009=\u2009400) and the WRAP\/WADRC (N\u2009=\u2009548) cohorts were included in the study. CSF biomarkers for core AD pathology (A\u03b242, A\u03b242\/40, p-tau181\/A\u03b242, p-tau181, p-tau217 and p-tau231), neurodegeneration (NfL, t-tau), synaptic dysfunction (neurogranin, GAP-43, SNAP25, synaptotagmin-1, \u03b1-synuclein), glial reactivity (GFAP, S100B, sTREM2, YKL-40), neuroinflammation (IL-6, MCP-1), and vascular dysregulation (sICAM-1, sVCAM-1) were measured. Participants underwent A\u03b2 PET at baseline and follow-up visit. We used Analyses of Covariance (ANCOVA) to evaluate sex differences in CSF biomarker levels and performed sex-stratified Receiver-Operating Characteristic (ROC) analyses to test their performance to identify A\u03b2 PET-positive individuals. Additionally, we run linear regression models to study the modifying effect of sex on the association of baseline CSF biomarkers with cross-sectional and longitudinal A\u03b2 PET uptake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Men had higher CSF NfL, glial reactivity and vascular dysregulation biomarkers (Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      ranging from -0.22 to -0.44,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), and lower synaptic biomarkers (Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      ranging from 0.18 to 0.30,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) compared to women\u00a0at baseline\n                      <jats:bold>.<\/jats:bold>\n                      There were no sex differences in the core AD CSF biomarkers\u2019 performance to identify A\u03b2 PET-positive individuals (DeLong's test\n                      <jats:italic>P<\/jats:italic>\n                      values\u2009&gt;\u20090.05), with CSF\u00a0p-tau181\/A\u03b242 and p-tau217 showing the highest performance in both sexes (Areas Under the Curve (AUCs) ranging from 87.1 to 96.3). However, sex modified the associations of baseline CSF biomarkers with A\u03b2 PET uptake, which were more pronounced in women than in men.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that tailoring core AD CSF biomarkers by sex is not necessary for detecting A\u03b2\u00a0PET\u00a0positivity in CU individuals. However, sex differences in their association with A\u03b2 deposition could influence their prognostic or monitoring applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01844-1","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:21:04Z","timestamp":1761801664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sex differences in Alzheimer\u2019s disease CSF biomarkers and their association with A\u03b2 pathology on PET in cognitively unimpaired individuals"],"prefix":"10.1186","volume":"17","author":[{"given":"Marta","family":"Mil\u00e0-Alom\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Van Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brugulat-Serrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Casals Brod\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Gonz\u00e1lez-Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"S\u00e1nchez-Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Shekari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castro-Aldrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Minguill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Novakova Martinkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Quijano-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendlyn","family":"Kollmorgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Schumacher Dimech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances-Catherine","family":"Quevenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Florencia","family":"Iulita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Fauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Domingo","family":"Gispert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Santuccione Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterling C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ALFA study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabella","family":"Beteta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Cacciaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Ca\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Deulofeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Emilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fern\u00e1ndez-Arcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherezade","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Genius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Grau-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Huesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Marne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje","family":"Pelkmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Pradas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Soteras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Stankeviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vilanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vilor-Tejedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"1844_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Fr\u00f6lich L, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2017;9: 60.","journal-title":"Alzheimers Res Ther"},{"key":"1844_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s43587-023-00410-4","volume":"3","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Aisen PS. Detection and treatment of Alzheimer\u2019s disease in its preclinical stage. Nat Aging. 2023;3:520\u201331.","journal-title":"Nat Aging"},{"key":"1844_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S1474-4422(22)00298-8","volume":"21","author":"CR Jack","year":"2022","unstructured":"Jack CR. Advances in Alzheimer\u2019s disease research over the past two decades. Lancet Neurol. 2022;21:866\u20139.","journal-title":"Lancet Neurol"},{"key":"1844_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","volume":"16","author":"M Mil\u00e0-Alom\u00e0","year":"2020","unstructured":"Mil\u00e0-Alom\u00e0 M, Salvad\u00f3 G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer\u2019s continuum. Alzheimers Dement. 2020;16:1358\u201371.","journal-title":"Alzheimers Dement"},{"key":"1844_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015;72:1029\u201342.","journal-title":"JAMA Neurol"},{"key":"1844_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2019.00315","volume":"11","author":"A Rahman","year":"2019","unstructured":"Rahman A, Jackson H, Hristov H, Isaacson RS, Saif N, Shetty T, et al. Sex and Gender Driven Modifiers of Alzheimer\u2019s: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. Frontiers in Aging Neuroscience. 2019;11:1\u201322.","journal-title":"Frontiers in Aging Neuroscience"},{"key":"1844_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1159435","volume":"15","author":"N Calvo","year":"2023","unstructured":"Calvo N, Einstein G. Steroid hormones: risk and resilience in women\u2019s Alzheimer disease. Front Aging Neurosci. 2023;15: 1159435.","journal-title":"Front Aging Neurosci"},{"key":"1844_CR8","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/brain\/awac177","volume":"145","author":"JM Eissman","year":"2022","unstructured":"Eissman JM, Dumitrescu L, Mahoney ER, Smith AN, Mukherjee S, Lee ML, et al. Sex differences in the genetic architecture of cognitive resilience to Alzheimer\u2019s disease. Brain. 2022;145:2541\u201354.","journal-title":"Brain"},{"key":"1844_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archpsyc.62.6.685","volume":"62","author":"LL Barnes","year":"2005","unstructured":"Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62:685\u201391.","journal-title":"Arch Gen Psychiatry"},{"key":"1844_CR10","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3174\/ajnr.A3601","volume":"34","author":"D Holland","year":"2013","unstructured":"Holland D, Desikan RS, Dale AM, McEvoy LK. Higher rates of decline for women and Apolipoprotein E \u03b54 carriers. AJNR Am J Neuroradiol. 2013;34:2287\u201393.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1844_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/ene.14174","volume":"27","author":"MT Ferretti","year":"2020","unstructured":"Ferretti MT, Martinkova J, Biskup E, Benke T, Gialdini G, Nedelska Z, et al. Sex and gender differences in Alzheimer\u2019s disease: current challenges and implications for clinical practice. Eur J Neurol. 2020;27:928\u201343.","journal-title":"Eur J Neurol"},{"key":"1844_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jalz.2018.08.003","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Ferretti MT, Iulita MF, Hayden K, Khachaturian AS. Sex and gender in Alzheimer\u2019s disease - does it matter? Alzheimers Dement. 2018;14:1101\u20133.","journal-title":"Alzheimers Dement"},{"key":"1844_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cca.2019.02.005","volume":"492","author":"C Bouter","year":"2019","unstructured":"Bouter C, Vogelgsang J, Wiltfang J. Comparison between amyloid-PET and CSF amyloid-\u03b2 biomarkers in a clinical cohort with memory deficits. Clin Chim Acta. 2019;492:62\u20138.","journal-title":"Clin Chim Acta"},{"key":"1844_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neurobiolaging.2019.02.019","volume":"78","author":"RF Buckley","year":"2019","unstructured":"Buckley RF, Mormino EC, Chhatwal J, Schultz AP, Rabin JS, Rentz DM, et al. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019;78:178\u201385.","journal-title":"Neurobiol Aging"},{"key":"1844_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2018.0821","volume":"75","author":"TJ Hohman","year":"2018","unstructured":"Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, et al. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75:989\u201398.","journal-title":"JAMA Neurol"},{"key":"1844_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0271-9","volume":"9","author":"G Li","year":"2017","unstructured":"Li G, Shofer JB, Petrie EC, Yu CE, Wilkinson CW, Figlewicz DP, et al. Cerebrospinal fluid biomarkers for Alzheimer\u2019s and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. Alzheimers Res Ther. 2017;9: 1\u20139.","journal-title":"Alzheimers Res Ther"},{"key":"1844_CR17","doi-asserted-by":"crossref","unstructured":"Duarte-Guterman P, Albert AY, Barha CK, Galea LAM, On Behalf Of The Alzheimer\u2019s Disease Neuroimaging Initiative null. Sex influences the effects of APOE genotype and Alzheimer\u2019s diagnosis on neuropathology and memory. Psychoneuroendocrinology. 2021;129:105248.","DOI":"10.1016\/j.psyneuen.2021.105248"},{"key":"1844_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ana.25878","volume":"88","author":"RF Buckley","year":"2020","unstructured":"Buckley RF, Scott MR, Jacobs HIL, Schultz AP, Properzi MJ, Amariglio RE, et al. Sex mediates relationships between regional tau pathology and cognitive decline. Ann Neurol. 2020;88:921\u201332.","journal-title":"Ann Neurol"},{"key":"1844_CR19","doi-asserted-by":"crossref","unstructured":"Koran MEI, Wagener M, Hohman TJ, Initiative for the AN. Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging and Behavior. 2017;11:205\u201313.","DOI":"10.1007\/s11682-016-9523-8"},{"key":"1844_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","volume":"75","author":"A Altmann","year":"2014","unstructured":"Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75:563\u201373.","journal-title":"Ann Neurol"},{"key":"1844_CR21","doi-asserted-by":"publisher","first-page":"8254","DOI":"10.1523\/JNEUROSCI.0305-12.2012","volume":"32","author":"JS Damoiseaux","year":"2012","unstructured":"Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, et al. Gender modulates the APOE 4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012;32:8254\u201362.","journal-title":"J Neurosci"},{"key":"1844_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010629","volume":"95","author":"R Babapour Mofrad","year":"2020","unstructured":"Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, et al. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE \u03b54 genotype. Neurology. 2020;95: e2378\u201388.","journal-title":"Neurology"},{"issue":"9","key":"1844_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cerme\u00f1o JC, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology. JAMA Neurol. 2019;76:1035.","journal-title":"JAMA Neurol"},{"key":"1844_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66090-x","volume":"10","author":"C Delaby","year":"2020","unstructured":"Delaby C, Alcolea D, Carmona-Iragui M, Ill\u00e1n-Gala I, Morenas-Rodr\u00edguez E, Barroeta I, et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep. 2020;10: 9161.","journal-title":"Sci Rep"},{"key":"1844_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neurobiolaging.2021.07.013","volume":"107","author":"B Lim","year":"2021","unstructured":"Lim B, Gr\u00f8ntvedt GR, Bathala P, Kale SS, Campbell CT, Stengelin M, et al. CSF neurofilament light may predict progression from amnestic mild cognitive impairment to Alzheimer\u2019s disease dementia. Neurobiol Aging. 2021;107:78\u201385.","journal-title":"Neurobiol Aging"},{"key":"1844_CR26","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol Med. 2016;8:1184\u201396.","journal-title":"EMBO Mol Med"},{"key":"1844_CR27","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jalz.2019.07.009","volume":"15","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Vemuri P, et al. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Alzheimers Dement. 2019;15:1437\u201347.","journal-title":"Alzheimers Dement"},{"key":"1844_CR28","volume":"13","author":"T Skillb\u00e4ck","year":"2021","unstructured":"Skillb\u00e4ck T, Blennow K, Zetterberg H, Shams S, Machado A, Pereira J, et al. Sex differences in CSF biomarkers for neurodegeneration and blood-brain barrier integrity. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13: e12141.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"1844_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40520-018-0948-3","volume":"31","author":"L Wang","year":"2019","unstructured":"Wang L, Alzheimer\u2019s Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurogranin with Alzheimer\u2019s disease. Aging Clin Exp Res. 2019;31:185\u201391.","journal-title":"Aging Clin Exp Res"},{"key":"1844_CR30","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.18632\/aging.103211","volume":"12","author":"M Xue","year":"2020","unstructured":"Xue M, Sun F-R, Ou Y-N, Shen X-N, Li H-Q, Huang Y-Y, et al. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer\u2019s disease. Aging. 2020;12:9365\u201379.","journal-title":"Aging"},{"key":"1844_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/labmed\/lmaa062","volume":"52","author":"L Agnello","year":"2021","unstructured":"Agnello L, Gambino CM, Lo Sasso B, Bivona G, Milano S, Ciaccio AM, et al. Neurogranin as a novel biomarker in Alzheimer\u2019s disease. Lab Med. 2021;52:188\u201396.","journal-title":"Lab Med"},{"key":"1844_CR32","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","volume":"89","author":"KB Casaletto","year":"2017","unstructured":"Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89:1782\u20138.","journal-title":"Neurology"},{"issue":"5","key":"1844_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. 2016;73:561.","journal-title":"JAMA Neurol"},{"key":"1844_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3233\/JAD-200982","volume":"78","author":"P Duarte-Guterman","year":"2020","unstructured":"Duarte-Guterman P, Albert AY, Inkster AM, Barha CK, Galea LAM, Alzheimer\u2019s Disease Neuroimaging Initiative. Inflammation in Alzheimer\u2019s disease: do sex and APOE matter? J Alzheimers Dis. 2020;78:627\u201341.","journal-title":"J Alzheimers Dis"},{"key":"1844_CR35","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867-77.","journal-title":"Neurology"},{"key":"1844_CR36","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2019.07.018","volume":"16","author":"F Brosseron","year":"2020","unstructured":"Brosseron F, Kolbe C, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, et al. Multicenter Alzheimer\u2019s and Parkinson\u2019s disease immune biomarker verification study. Alzheimers Dement. 2020;16:292\u2013304.","journal-title":"Alzheimers Dement"},{"key":"1844_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1399-2","volume":"16","author":"K Nordengen","year":"2019","unstructured":"Nordengen K, Kirsebom B-E, Henjum K, Selnes P, G\u00edslad\u00f3ttir B, Wettergreen M, et al. Glial activation and inflammation along the Alzheimer\u2019s disease continuum. J Neuroinflammation. 2019;16: 46.","journal-title":"J Neuroinflammation"},{"key":"1844_CR38","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/alz.12245","volume":"17","author":"G Salvad\u00f3","year":"2021","unstructured":"Salvad\u00f3 G, Mil\u00e0-Alom\u00e0 M, Shekari M, Minguillon C, Fauria K, Ni\u00f1erola-Baiz\u00e1n A, et al. Cerebral amyloid-\u03b2 load is associated with neurodegeneration and gliosis: mediation by p-tau and interactions with risk factors early in the Alzheimer\u2019s continuum. Alzheimers Dement. 2021;17:788\u2013800.","journal-title":"Alzheimers Dement"},{"key":"1844_CR39","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41380-024-02753-9","volume":"30","author":"C Vila-Castelar","year":"2025","unstructured":"Vila-Castelar C, Akinci M, Palpatzis E, Aguilar-Dominguez P, Operto G, Kollmorgen G, et al. Sex\/gender effects of glial reactivity on preclinical Alzheimer\u2019s disease pathology. Mol Psychiatry. 2025;30:1430\u20139.","journal-title":"Mol Psychiatry"},{"key":"1844_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.trci.2016.02.003","volume":"2","author":"JL Molinuevo","year":"2016","unstructured":"Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, et al. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2016;2:82\u201392.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1844_CR41","first-page":"130","volume":"10","author":"SC Johnson","year":"2018","unstructured":"Johnson SC, Koscik RL, Jonaitis EM, Clark LR, Mueller KD, Berman SE, et al. The Wisconsin registry for Alzheimer\u2019s prevention: a review of findings and current directions. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2018;10:130\u201342.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"1844_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-170602","volume":"62","author":"BM Bettcher","year":"2018","unstructured":"Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, et al. CSF and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer\u2019s Disease Pathology and Neuronal Damage HHS Public Access. J Alzheimers Dis. 2018;62:385\u201397.","journal-title":"J Alzheimers Dis"},{"key":"1844_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"1844_CR44","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.trci.2017.10.004","volume":"3","author":"KV Papp","year":"2017","unstructured":"Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer\u2019s cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y). 2017;3:668\u201377.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"22","key":"1844_CR45","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue MC, Sperling RA, Petersen R, Sun C-K, Weiner MW, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317:2305.","journal-title":"JAMA"},{"key":"1844_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med. 2020;12:1\u201319.","journal-title":"EMBO Mol Med"},{"key":"1844_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12204","author":"C Van Hulle","year":"2020","unstructured":"Van Hulle C, Jonaitis EM, Betthauser TJ, Batrla R, Wild N, Kollmorgen G, et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer\u2019s disease clinical and pathological continuum. Alzheimers Dement.\u00a02021;17:431-445.","journal-title":"Alzheimers Dement"},{"key":"1844_CR48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"1844_CR49","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739\u201352.","journal-title":"Lancet Neurol"},{"key":"1844_CR50","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","volume":"95","author":"M Tible","year":"2020","unstructured":"Tible M, Sandelius \u00c5, H\u00f6glund K, Brinkmalm A, Cognat E, Dumurgier J, et al. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology. 2020;95:e953-61.","journal-title":"Neurology"},{"key":"1844_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15:55\u201364.","journal-title":"Alzheimers Dement"},{"key":"1844_CR52","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1002\/alz.13883","volume":"20","author":"M Shekari","year":"2024","unstructured":"Shekari M, V\u00e1llez Garc\u00eda D, Collij LE, Altomare D, Heeman F, Pemberton H, et al. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology. Alzheimers Dement. 2024;20:5102\u201313.","journal-title":"Alzheimers Dement"},{"key":"1844_CR53","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2013.09.028","volume":"35","author":"SC Johnson","year":"2014","unstructured":"Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, et al. Amyloid burden and neural function in people at risk for Alzheimer\u2019s disease. Neurobiol Aging. 2014;35:576\u201384.","journal-title":"Neurobiol Aging"},{"key":"1844_CR54","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1093\/brain\/awac213","volume":"145","author":"TJ Betthauser","year":"2022","unstructured":"Betthauser TJ, Bilgel M, Koscik RL, Jedynak BM, An Y, Kellett KA, et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain. 2022;145:4065\u201379.","journal-title":"Brain"},{"key":"1844_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e4.","journal-title":"Alzheimers Dement"},{"key":"1844_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14406","author":"RE Rea Reyes","year":"2024","unstructured":"Rea Reyes RE, Cody KA, Wilson RE, Zetterberg H, Chin NA, Jonaitis EM, et al. Visual read of [F-18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer\u2019s disease. Alzheimers Dement. 2025;21:e14406.","journal-title":"Alzheimers Dement"},{"key":"1844_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"1844_CR58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF A \u03b2 42\/A \u03b2 40 and A \u03b2 42\/A \u03b2 38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365.","journal-title":"Ann Clin Transl Neurol"},{"key":"1844_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20:5143\u20135169.","journal-title":"Alzheimers Dement"},{"key":"1844_CR60","doi-asserted-by":"crossref","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2023;80:188\u2013199.","DOI":"10.1001\/jamaneurol.2022.4485"},{"key":"1844_CR61","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13: e14022.","journal-title":"EMBO Mol Med"},{"key":"1844_CR62","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989\u201397.","journal-title":"Alzheimers Dement"},{"key":"1844_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00578-0","volume":"17","author":"ME Murray","year":"2022","unstructured":"Murray ME, Moloney CM, Kouri N, Syrjanen JA, Matchett BJ, Rothberg DM, et al. Global neuropathologic severity of Alzheimer\u2019s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Mol Neurodegener. 2022;17: 85.","journal-title":"Mol Neurodegener"},{"key":"1844_CR64","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaneurol.2023.0455","volume":"80","author":"GT Coughlan","year":"2023","unstructured":"Coughlan GT, Betthauser TJ, Boyle R, Koscik RL, Klinger HM, Chibnik LB, et al. Association of age at menopause and hormone therapy use with tau and \u03b2-amyloid positron emission tomography. JAMA Neurol. 2023;80:462\u201373.","journal-title":"JAMA Neurol"},{"key":"1844_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00310-x","volume":"11","author":"EE Sundermann","year":"2020","unstructured":"Sundermann EE, Panizzon MS, Chen X, Andrews M, Galasko D, Banks SJ. Sex differences in Alzheimer\u2019s-related tau biomarkers and a mediating effect of testosterone. Biol Sex Differ. 2020;11: 33.","journal-title":"Biol Sex Differ"},{"key":"1844_CR66","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1523\/JNEUROSCI.19-10-04065.1999","volume":"19","author":"RC Gur","year":"1999","unstructured":"Gur RC, Turetsky BI, Matsui M, Yan M, Bilker W, Hughett P, et al. Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance. J Neurosci. 1999;19:4065\u201372.","journal-title":"J Neurosci"},{"key":"1844_CR67","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, et al. CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET. Neurology. 2021;97:e2065\u201378.","journal-title":"Neurology"},{"key":"1844_CR68","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1111\/jcmm.13767","volume":"22","author":"C Parrado-Fern\u00e1ndez","year":"2018","unstructured":"Parrado-Fern\u00e1ndez C, Blennow K, Hansson M, Leoni V, Cedazo-Minguez A, Bj\u00f6rkhem I. Evidence for sex difference in","journal-title":"J Cell Mol Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01844-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:04:25Z","timestamp":1761807865000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01844-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1844"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01844-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ALFA+ study protocol has been approved by an independent Ethics Committee Parc de Salut Mar Barcelona and registered at Clinicaltrials.gov (ALFA+ Identifier:\u00a0NCT02485730). The study has been conducted in accordance with the directives of the Spanish Law 14\/2007, of 3rd of July, on Biomedical Research (Ley 14\/2007 de Investigaci\u00f3n Biom\u00e9dica). All the participants gave written consent to participate in the study.\u00a0All WRAP\/ADRC participants or their caregivers provided informed written consent according to the Declaration of Helsinki. Study procedures were approved by the University of Wisconsin-Madison Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MSC has received in the past 36mo consultancy\/speaker fees (paid to the institution) from by Almirall, Eli Lilly, Novo Nordisk, and Roche Diagnostics. He has received consultancy fees or served on advisory boards (paid to the institution) of Eli Lilly, Grifols and Roche Diagnostics. He was granted a project and is a site investigator of a clinical trial (funded to the institution) by Roche Diagnostics. In-kind support for research (to the institution) was received from ADx Neurosciences, Alamar Biosciences, ALZPath, Avid Radiopharmaceuticals, Eli Lilly, Fujirebio, Janssen Research & Development, Meso Scale Discovery, and Roche Diagnostics; MSC did not receive any personal compensation from these organizations or any other for-profit organization.\u00a0JDG has received research support from GE HealthCare, Roche Diagnostics, Hoffmann \u2013 La Roche and Life \u2013 MI, has participated in symposia sponsored by Biogen, Philips Nederlands, Life-MI and Esteve, acted as a consultant for Roche Diagnostics and served in the Molecular Neuroimaging Advisory Board of Prothena Biosciences. JDG is founder, co-owner and member of the Board of Directors of Betascreen SL. JDG is currently a full-time employee of AstraZeneca.\u00a0SCJ has received consultancy fees or served on advisory boards for ALZPath, Enigma Biomedical, Eli Lilly and Quanterix.\u00a0MTF is an employee of Syntropic Medical GmbH. In the past 3 years she has received speaking and consulting fees from Prodeco Pharma, Angelini Pharma, Roche, EPG Health unrelated to this project.\u00a0MCT has received consultancy fees from Eli Lilly, Eisai and Novo nordisk. MCT has received funding from Roche. MCT is an site investigator for clinical trials with Anavex, Janssen, UCB, Novo nordisk, Passage Bio, Bristol Meyers Squibb, and Aribio.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}